Stocky turns companies like BIOINVENT INTERNATIONAL AB BIOI into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. 0H22.L scores poorly on Value Compounder metrics (12/100), indicating weak cash generation and profitability relative to valuation. Leadership Alignment (45/100) suggests misalignment between insiders and shareholders, raising governance concerns. While the Vulnerability Index shows no immediate structural moats under pressure, the combination of weak economics and governance drift outweighs any near-term resilience.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for BIOINVENT INTERNATIONAL AB BIOI:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 17/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates BIOINVENT INTERNATIONAL AB BIOI (0H22.L) at 17/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 0H22.L scores poorly on Value Compounder metrics (12/100), indicating weak cash generation and profitability relative to valuation. Leadership Alignment (45/100) suggests misalignment between insiders and shareholders, raising govern
0H22.L's current Stocky Verdict is 17/100, placing it in the "Avoid" band. This composite combines a 12/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for BIOINVENT INTERNATIONAL AB BIOI yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
BIOINVENT INTERNATIONAL AB BIOI scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
BIOINVENT INTERNATIONAL AB BIOI's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to BIOINVENT INTERNATIONAL AB BIOI.
Sign up free and unlock the full analysis on 0H22.L — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 0H22.L in the app.
